DIVI'S LABORATORIES LTD. - 532488 - Board Meeting Outcome for Outcome Of Board Meeting Held On May 23, 2022
As per enclosed.23-05-2022
23-05-2022
DIVI'S LABORATORIES LTD. - 532488 - Board recommends Dividend
Divis Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 23, 2022, inter alia, has recommended a Dividend of Rs. 30/- (i.e. 1500%) per equity share of face value Rs. 2/- each for the financial year 2021-22, subject to approval of the members at the ensuing 32nd Annual General Meeting (AGM). The dividend shall be credited/ warrants thereof dispatched within 30 (thirty) days from the conclusion of the AGM.23-05-2022
DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of earnings conference call Q4 and full year FY2216-05-2022
DIVI'S LABORATORIES LTD. - 532488 - Board Meeting Intimation for Considering And Approving Audited Standalone And Consolidated Financial Results For The Fourth Quarter And Year Ended March 31, 2022 And Recommend Dividend, If Any, On Equity Shares Of The Company For The Financial Year 2021-22
DIVI''s LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2022 ,inter alia, to consider and approve audited standalone and consolidated financial results for the fourth quarter and year ended March 31, 2022 and to recommend dividend, if any, on equity shares of the Company for the financial year 2021-22. As intimated earlier, the Trading Window for dealing in securities of the Company has been closed from April 01, 2022 till 48 hours after the declaration of financial results as per the Code of Conduct of the Company pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015.13-05-2022
DIVI'S LABORATORIES LTD. - 532488 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular no CIR/CFD/CMD1/27/2019 dated February 08, 2019, we hereby submit the Annual Secretarial Compliance Report for the year ended March 31, 2022 issued by Mr. V. Bhaskara Rao, Practicing Company Secretary, Hyderabad. This is for your information and records.12-05-2022
DIVI'S LABORATORIES LTD. - 532488 - Certificate Pursuant To Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended March 31, 2022
Please find the enclosed certificate dated April 12, 2022 obtained from V. Bhaskara Rao & Co., Company Secretaries for the year ended March 31, 2022, pursuant to Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.12-04-2022
DIVI'S LABORATORIES LTD. - 532488 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayDIVI''S LABORATORIES LTD. 2CINL24110TG1990PLC011854 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY AA+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CARE RATINGS LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: M Satish Choudhury Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: L. Kishore Babu Designation: Chief Financial Officer EmailId: [email protected] Date: 12/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.12-04-2022
DIVI'S LABORATORIES LTD. - 532488 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- M Satish ChoudhuryDesignation :- Company Secretary and Compliance Officer11-04-2022